Bausch & Lomb vs. Lupin: Ophthalmic Patent Dispute Ends in Stipulated Dismissal

Introduction

In a case that underscores the complex interplay between pharmaceutical patent enforcement and generic drug competition, Bausch & Lomb, Inc. and Lupin Limited resolved their ophthalmic suspension patent dispute through a stipulated dismissal without prejudice — leaving the door open for future litigation while avoiding a full adjudication on the merits. Filed in February 2023 in the U.S. District Court for the District of New Jersey and closed in January 2026, Case No. 2:23-cv-00790 centered on U.S. Patent No. US10596107B2, covering an ophthalmic suspension composition. The case drew representation from well-regarded New Jersey IP litigation firms on both sides.

For patent attorneys, IP professionals, and R&D teams operating in the ophthalmic pharmaceutical space, this dismissal carries meaningful strategic implications — from ANDA litigation posture to freedom-to-operate assessments. Understanding why sophisticated parties choose negotiated exits over adjudication is critical intelligence for anyone navigating pharmaceutical patent infringement disputes.

Case Overview

The Parties

The Patent at Issue

The asserted patent, U.S. Patent No. US10596107B2 (Application No. US15/006525), covers an **ophthalmic suspension composition** — a formulation technology relevant to eye drop products. Ophthalmic suspension patents frequently become litigation flashpoints because their claims can encompass specific particle sizes, excipients, and stabilization methods that define a product’s commercial viability and regulatory pathway.

The litigation targeted an **ophthalmic suspension composition**, consistent with the Hatch-Waxman framework where a generic manufacturer’s ANDA filing referencing a branded ophthalmic product constitutes a technical act of infringement sufficient to trigger litigation.

Legal Representation

Plaintiff (Bausch & Lomb): Gibbons PC and Sills Cummis & Gross P.C., represented by Caroline E. Oks, Danielle N. Craft, J. Brugh Lower, Stephen R. Donat, Steven Fernandez, and William P. Deni, Jr.
Defendant (Lupin Limited): Midlige Richter LLC, represented by James S. Richter and Kurt A. Mathas.

Both sides engaged counsel with deep pharmaceutical patent litigation experience — a hallmark of high-stakes ANDA disputes in New Jersey federal court.

Litigation Timeline & Procedural History

Filed: February 10, 2023
Closed: January 5, 2026
Duration: 1,060 days (approximately 2 years, 10 months)

The District of New Jersey was the natural venue choice — it is one of the nation’s most active jurisdictions for Hatch-Waxman pharmaceutical patent litigation, given New Jersey’s concentration of major pharmaceutical companies and the court’s institutional familiarity with complex patent disputes.

The case ran for nearly three years at the district court level before resolution, a duration typical of pharmaceutical patent cases that proceed through claim construction briefing, fact discovery, and expert preparation before settlement discussions crystallize. Specific procedural milestones — including any Markman hearings, summary judgment motions, or claim construction rulings — were not publicly disclosed in the record summary available. The case closed at the first instance (district court) level, meaning no appellate proceedings were initiated.

The Verdict & Legal Analysis

Outcome

The parties filed a stipulated dismissal pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii), jointly agreeing to dismiss all claims, counterclaims, and affirmative defenses without prejudice and without costs or attorneys’ fees to either party.

No damages were awarded. No injunctive relief was granted or denied. The case did not produce a court-adjudicated finding on patent validity or infringement.

What a Rule 41(a)(1)(A)(ii) Dismissal Signals

A dismissal under FRCP 41(a)(1)(A)(ii) requires a signed stipulation from all parties — signaling a negotiated resolution rather than a unilateral withdrawal. The “without prejudice” designation is legally significant: Bausch & Lomb retains the right to re-assert U.S. Patent No. US10596107B2 against Lupin in a future proceeding if circumstances change, such as an amended ANDA, a new product launch, or revised claim interpretation.

The absence of a cost-shifting provision suggests a clean, arms-length resolution — neither party extracted a financial concession as a condition of dismissal, which often indicates a confidential licensing arrangement or a commercial agreement governing Lupin’s market entry reached contemporaneously with the dismissal.

Verdict Cause Analysis

The infringement action arose from Lupin’s ophthalmic suspension product, with Bausch & Lomb asserting that the generic formulation fell within the scope of the ‘107 patent’s claims. Pharmaceutical patent defendants in this posture typically advance invalidity challenges (obviousness under 35 U.S.C. § 103, enablement under § 112) alongside non-infringement positions.

Because the case resolved without a merits adjudication, there is no public record of claim construction rulings or validity findings. However, the near-three-year litigation duration suggests the parties engaged in substantial discovery and expert preparation — the traditional precursors to a settlement when both sides gain clarity on litigation risk.

Legal Significance

The without-prejudice dismissal creates no binding precedent on the validity or enforceability of U.S. Patent No. US10596107B2. This means Bausch & Lomb’s patent remains intact and fully assertable — a critical distinction for competitors and generic manufacturers evaluating freedom-to-operate in the ophthalmic suspension space.

Strategic Takeaways

For Patent Holders:
Bausch & Lomb’s decision to accept a without-prejudice dismissal preserves patent leverage for future enforcement. Brand pharmaceutical companies increasingly use this approach when a negotiated commercial resolution (e.g., an authorized generic arrangement or delayed market entry agreement) is preferable to the uncertainty of trial.

For Accused Infringers:
Lupin’s successful navigation to a dismissal without costs or fee-shifting reflects effective litigation strategy. Generic manufacturers should ensure their ANDA paragraphs IV certifications are supported by robust invalidity and non-infringement analyses to create credible settlement leverage.

For R&D Teams:
The survival of U.S. Patent No. US10596107B2 without any invalidation finding means ophthalmic suspension formulators must conduct thorough **freedom-to-operate (FTO) analyses** before commercializing competing compositions. The patent’s claims — covering suspension formulation technology — should be mapped against any proposed generic or branded formulation in this therapeutic category.

Industry & Competitive Implications

The Bausch & Lomb v. Lupin dismissal reflects broader trends reshaping pharmaceutical patent litigation strategy. Hatch-Waxman cases increasingly resolve through negotiated settlements as both brand and generic companies weigh litigation costs against commercial certainty. For Bausch & Lomb, protecting its ophthalmic franchise against generic erosion is a persistent strategic priority; for Lupin, securing U.S. market entry — even on negotiated terms — represents a significant commercial objective.

The ophthalmic pharmaceutical sector has seen sustained patent litigation activity, with formulation patents (covering suspension stability, excipient composition, and drug delivery mechanisms) serving as the primary battleground. A patent covering ophthalmic suspension composition technology holds considerable commercial value given the volume of branded ophthalmic products facing generic competition.

This case also reflects the continued strategic importance of the District of New Jersey as the preeminent venue for pharmaceutical IP disputes — patent litigators should anticipate that the court’s developed Hatch-Waxman jurisprudence will continue attracting high-value cases between major pharmaceutical patent holders and generic challengers.